tiprankstipranks

Helen Thackray Insider Profile

4 Followers
Helen Thackray, SVP Clinical Development, CMO at GlycoMimetics, holds 272.14K shares in BioCryst (Ticker: BCRX), holds 0.00 shares in ImmunoGen (Ticker: IMGN), holds 183.12K shares in GlycoMimetics (Ticker: GLYC). Most recently, Helen Thackray Bought ― shares of BioCryst on May 15, 2024 for an estimated value of 175.80K.
tipranks
Helen Thackray

Helen Thackray
GlycoMimetics (GLYC)
SVP Clinical Development, CMO

Not Ranked
Helen Thackray has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
1 Year
Compare to
No Benchmark

Insider Holdings

$2M
97.51%
2.49%
A breakdown of Helen Thackray's holdings

Insider Roles

BioCryst
(BCRX)
Chief R&D Officer
GlycoMimetics
(GLYC)
SVP Clinical Development, CMO
Roles that Helen Thackray holds in companies

Most Profitable Insider Trade

Stock:
BioCryst
(BCRX)
Rating:Informative Buy
Date:May 15, 2024 - Today
Return:+1.50%
The most profitable trade made by Helen Thackray

Helen Thackray's Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
GlycoMimetics
Jan 22, 2021
SVP Clinical Development, CMO
Uninformative Buy
$43.40K
BioCryst
May 15, 2024
Chief R&D Officer
Informative Buy
175.80K
$1.70M
IMGN
ImmunoGen
Feb 12, 2024
Uninformative Sell
$0.00
List of latest transactions for each holding click on a transaction to see Helen Thackray's performance on stock

Helen Thackray insider profile FAQ

What is the percentage of profitable transactions made by Helen Thackray?
The percentage of profitable transactions made by Helen Thackray is ―.
    What is the average return per transaction made by Helen Thackray?
    The average return per transaction made by Helen Thackray is ―.
      What stocks does Helen Thackray hold?
      Helen Thackray holds: GLYC, BCRX, IMGN stocks.
        What was Helen Thackray’s latest transaction?
        Helen Thackray latest transaction was an Informative Buy of $175.80K.
          What was Helen Thackray's most profitable transaction?
          Helen Thackray’s most profitable transaction was an Informative Buy of BCRX stock on May 15, 2024. The return on the trade was 1.50%.
            What is Helen Thackray's role in GlycoMimetics?
            Helen Thackray's role in GlycoMimetics is SVP Clinical Development, CMO.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.